Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
DELYTACT® Oncolytic Virus G47∆ Approved in Japan for Treatment of Patients with Malignant GliomaDaiichi Sankyo2021-06-11 17:41:55DELYTACT® Oncolytic Virus G47∆ Approved in Japan for Treatment of Patients with Malignant Glioma
-
Valemetostat Data at EHA Shows Promising Durable Tumor Response in Patients with Peripheral T-Cell Lymphoma and Adult T-Cell Leukemia/LymphomaDaiichi Sankyo2021-06-11 09:11:05Valemetostat Data at EHA Shows Promising Durable Tumor Response in Patients with Peripheral T-Cell Lymphoma
-
Patritumab Deruxtecan Data at ASCO Demonstrates Tumor Response Across Multiple Resistance Mechanisms in Patients with Advanced EGFR-Mutated NSCLCDaiichi Sankyo2021-06-04 14:10:11Patritumab Deruxtecan Data at ASCO Demonstrates Tumor Response Across Multiple Resistance Mechanisms in
-
Daiichi Sankyo Advances Science Across Three Lead DXd ADCs with New Data in Multiple Cancers at 2021 ASCO Virtual MeetingDaiichi Sankyo2021-06-04 10:39:54Daiichi Sankyo Advances Science Across Three Lead DXd ADCs with New Data in Multiple Cancers at 2021 ASCO
-
Datopotamab Deruxtecan Late-Breaking Data at ESMO Breast Shows Promising Preliminary Response and Disease Control in Patients with Metastatic Triple Negative Breast CancerDaiichi Sankyo2021-05-07 09:29:00Datopotamab Deruxtecan Late-Breaking Data at ESMO Breast Shows Promising Preliminary Response and Disease
-
ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCERDaiichi Sankyo2021-04-20 08:41:52ENHERTU® ▼ (TRASTUZUMAB DERUXTECAN) NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2
-
Daiichi Sankyo Initiates Phase 2 Trial to Evaluate Pexidartinib in Japanese Patients with TGCTDaiichi Sankyo2021-04-09 09:03:00Daiichi Sankyo Initiates Phase 2 Trial to Evaluate Pexidartinib in Japanese Patients with TGCT
-
Phase 1/2 Trial Initiated for Daiichi Sankyo’s Menin Inhibitor DS-1594 in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic LeukemiaDaiichi Sankyo2021-04-07 09:27:33Phase 1/2 Trial Initiated for Daiichi Sankyo’s Menin Inhibitor DS-1594 in Patients with Acute Myeloid Leukemia
-
DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Overexpressing Advanced Colorectal CancerDaiichi Sankyo2021-04-06 09:43:21DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Overexpressing Advanced Colorectal
-
DESTINY-Lung02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Mutated Metastatic Non-Small Cell Lung CancerDaiichi Sankyo2021-03-29 09:32:36DESTINY-Lung02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Mutated Metastatic Non-Small Cell
